Xenon Pharmaceuticals Inc. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d003a910-8bd3-4e05-8307-05cf418435b3/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-345.9M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-076650 |
| FY 2024 | $-234.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-029149 |
| FY 2023 | $-182.4M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-023177 |
| FY 2022 | $-125.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-005582 |
| FY 2021 | $-78.9M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-008060 |
| FY 2020 | $-28.8M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009905 |
| FY 2019 | $-41.6M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-009385 |
| FY 2018 | $-34.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006514 |
| FY 2017 | $-30.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004750 |
| FY 2016 | $-23.0M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003716 |
| FY 2015 | $-15.8M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014222 |
| FY 2014 | $13.0M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001612 |
| FY 2013 | $12.0M | 2013-01-01 – 2013-12-31 | evidence 0001171843-14-005910 |
| FY 2012 | $-4.3M | 2012-01-01 – 2012-12-31 | evidence 0001564590-15-001612 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Xenon Pharmaceuticals Inc. — all facts · Revenue · Operating Income